Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Trader Note — 15017 total
Arcus Biosciences has gained 22% over the past month and 9% on the week, yet short sellers are simultaneously adding to positions at the fastest pace in months — a tension that defines the setup heading into August…
Guardant Health closes the week at $150.03 — up 15% in seven days — with its co-founder selling aggressively into the strength and analysts still racing to catch up with the move. The insider story is the clearest…
HLMN enters the first week of July having delivered its best monthly run in some time — up 13% over the past month and 8.5% on the week alone to close at $8.44 — yet a sharp and sudden rebuild in short positioning is…
Merchants Bancorp heads into its July 28 earnings with a notable analyst defection, a sharp rebuild in short interest, and a stock that has quietly reclaimed the $50 level. The standout this week is the rating change.…
IperionX closes the week at A$4.08 — down 30% over the past month — yet the most interesting tension is not the price itself but what the ORTEX short score is quietly doing in the background as the stock rebounds off…
Knight-Swift enters the final week of Q2 with a notable convergence: the Street has been sharply upgrading its view just as short sellers accelerate their exit, leaving the stock priced at a modest discount to where…
Cannae Holdings enters July with shorts unwinding and the stock up 4.4% on the week — yet the gap between the share price and underlying asset value remains the central tension for investors. Short sellers have been…
OPTU heads into July with a stock that has more than doubled in a month yet faces a lending market tightening at a pace that demands attention. The most striking development this week is how quickly borrow availability…
Baker Hughes has dropped another 5.4% this week to $55.50, extending a painful month that has now erased 13% — and the C-suite selling flagged in last week's note looks increasingly well-timed. The insider angle has…
Charter Communications heads into Q2 earnings season with a fractured setup: short sellers are trimming positions after a bruising spring, but the stock is still one of the most heavily shorted names in US cable, and…
JPSE — the JPMorgan Diversified Return U.S. Small Cap Equity ETF — enters July with a quiet but notable shift in its lending market, even as the underlying price trend remains constructive. The standout this week is…
Alcoa ends June with a worsening picture: the stock dropped another 5% on the week to $52.14, shorts are rebuilding at their fastest pace in months, and Q1 earnings in two weeks offer the next real test of whether the…
CRISPR Therapeutics heads into the second half of 2026 carrying one of the most charged short-side setups in biotech — short interest has jumped 20% in a single week while the stock trails its gene-editing peers by a…
FB Financial Corporation heads into its July 13 earnings report with short sellers quietly rebuilding positions while the analyst community moves in the opposite direction. The standout tension this week is timing.…
First Hawaiian heads into its July 24 earnings report having outrun most of its regional bank peers, while the Street remains firmly in hold-or-sell territory — a tension that sharpens as the stock has now exceeded the…
CRVS enters July with a striking contradiction at its core: the stock has rallied 18% in a week and 20% over the past month to close at $14.94, yet short sellers have not retreated — they have added to positions. Short…
BeOne Medicines enters July with short sellers voting heavily with their feet — and the borrow market confirming there's almost no conviction left on the bearish side. Short interest has collapsed over the past month,…
Altimmune enters July with one of the most heavily shorted positions in small-cap biotech, even as the stock edges higher and insiders continue to put their own money in. Short interest is the defining story here, and…
SPCX at $170.86 is a stock with a $190 bull target, a $115 bear target, and a Nasdaq 100 rebalance landing in two days — the Street's first week of formal coverage has produced no consensus whatsoever. The analyst…
HUBB heads into its July 28 earnings date with shorts quietly rebuilding, borrowing costs climbing, and the stock trading near all-time highs — a combination that makes the setup worth watching. Short interest has been…
